Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked [Seeking Alpha]
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: Seeking Alpha
XENE plans an NDA submission for azetukalner in Q3 2026, targeting both epilepsy and neuropsychiatric indications, with additional pivotal trials ongoing. Despite robust efficacy and a differentiated profile, XENE faces a crowded anti-seizure market, notable adverse event rates, and potential commercial execution risks. I view XENE's $5bn valuation as pricing in approval and commercial success, so I refrain from a Buy rating given dilution and execution risks. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » koto_feja/iStock via Getty Images Investment Overview Xenon Pharmaceuticals Inc. ( XENE completed its Initial Public Offering in November 2014, issuing 4m shares priced at $9 per share. As of the close of business on Friday 6th March, the stock traded at $42 per More on my IG service If you are interested in keeping up to date with stocks making moves within the bio
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon Pharmaceuticals (XENE) had its price target lowered by Wedbush from $64.00 to $63.00. They now have an "outperform" rating on the stock.MarketBeat
- Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Assessing Xenon Pharmaceuticals (XENE) Valuation After A Sharp Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewswire
XENE
Earnings
- 2/26/26 - Miss
XENE
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- XENE's page on the SEC website